System Biology of Spleen Deficiency Syndrome
System Biology of Spleen Deficiency Syndrome
Spleen Deficiency Syndrome(SDS)is a widely researched issue, but due to the limitations of
 the research methods, the scientific mechanism of SDS is biased and not comprehensive. SDS
 would be researched in this project deeply and systematically with modern life-scientific
 methods. Based on the previous work, the participants, with SDS, suffering from Qi deficiency
 syndrome--chronic superficial gastritis--chronic atrophic gastritis--gastric cancer would be
 included, and the corresponding research would be conducted at the molecular-cell-gastric
 tissue level, and at the same time, systematical biological database of SDS would be built by
 systematical biological methods, such as pioneered SPARS sequencing technology created in our
 research group, proteomics and metabonomics. Under the above work, the investigators would
 conduct data mining and molecular network analysis, and then verify the key functions. By
 analyzing the systematical biological features of syndrome and its relationships with
 constitution and disease, this study would provide a new basis for objective reality of
 syndrome, and also offer a crucial premise of revealing biological basis for syndrome
 correctly, which is of important theoretical and practical significance.
Inclusion Criteria:

 -  Aged between 18 and 65 years.

 -  No apparent abnormality in the routine blood test, urinalysis, routine stool & fecal
 occult blood test, biochemical test, chest radiograph and electrocardiogram(ECG).

 -  The endoscopic diagnoses of chronic superficial gastritis, chronic atrophic gastritis
 and gastric cancer conform to the corresponding pathological diagnoses

 -  TCM diagnoses of Spleen-qi Deficiency Syndrome or Spleen Damp-heat Syndrome.

 -  Voluntary participation.

 -  Having given written informed consent.

 Exclusion Criteria:

 -  Gastropathy with special causes, such as acute gastritis, gastrinoma, chronic
 gastritis resulting from special causes (like granulomatous gastritis, lymphocytic
 gastritis, eosinophilic gastritis, gastritis after gastric operation) peptic ulcer,
 other malignant tumors of stomach (like gastric lymphoma, gastri stromal tumor,
 carcinoid tumor, malignant hemangioma, squamous-cell carcinoma, primary gastric
 choriocarcinoma and metastatic gastric tumor), benign gastritic tumors that originate
 from epithelium or submucosa (epithelial tumors like adenomatous polyps and
 hyperplastic polyps, stromal tumors like benign stromal tumor, neuronal tumor and
 pseudolymphoma).

 -  Combined with other digestive diseases (like gastroesophageal reflux, esophageal
 varices, acute and chronic hepatitis and cirrhosis arising from various causes,
 acute/chronic pancreatitis and acute/chronic cholecystitis).

 -  Combined with other severe systemic diseases such as respiratory failure, severe
 cardiovascular and cerebrovascular, immune system, urinary and mental disorders
 diseases.

 -  Pregnancy, or planning pregnancy during the trial or within three month period
 thereafter.

 -  Participation in any clinical trial including blood sampling and/or administration of
 substances up to 90 days before Day 01 of this study.